OP0237 THROMBOEMBOLIC SAFETY PROFILE OF TOFACITINIB AND BARICITINIB: AN ANALYSIS OF WHO VIGIBASE

E. Vallejo-Yagüe; S. Weiler; A. M. Burden

doi:10.1136/annrheumdis-2020-eular.2823

Article info

PDF

Scientific Abstracts

Oral Presentations

Rheumatoid arthritis - non biologic treatment and small molecules

OP0237 THROMBOEMBOLIC SAFETY PROFILE OF TOFACITINIB AND BARICITINIB: AN ANALYSIS OF WHO VIGIBASE

Free

Authors

E. Vallejo-Yagüe ETH Zürich, Department of Chemistry and Applied Biosciences, Zürich, Switzerland PubMed articles Google scholar articles
S. Weiler ETH Zürich, Department of Chemistry and Applied Biosciences, Zürich, SwitzerlandNational Poisons Information Centre, Tox Info Suisse, Associated Institute of the University of Zurich, Zurich, Switzerland PubMed articles Google scholar articles
A. M. Burden ETH Zürich, Department of Chemistry and Applied Biosciences, Zürich, Switzerland PubMed articles Google scholar articles

Citation

Vallejo-Yagüe E, Weiler S, Burden AM

OP0237 THROMBOEMBOLIC SAFETY PROFILE OF TOFACITINIB AND BARICITINIB: AN ANALYSIS OF WHO VIGIBASE

Annals of the Rheumatic Diseases 2020;79:150.

Publication history

First published June 2, 2020.

Online issue publication

January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password